Propylnitazene

Propylnitazene
Identifiers
	IUPAC name N,N-diethyl-2-[5-nitro-2-[(4-propylphenyl)methyl]benzimidazol-1-yl]ethanamine;
CAS Number	700342-00-3;
PubChem CID	162623877;
ChemSpider	129433049;
UNII	TN458A7BPE;
Chemical and physical data
Formula	C23H30N4O2
Molar mass	394.519 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCC1=CC=C(C=C1)CC2=NC3=C(N2CCN(CC)CC)C=CC(=C3)[N+](=O)[O-];
	InChI InChI=1S/C23H30N4O2/c1-4-7-18-8-10-19(11-9-18)16-23-24-21-17-20(27(28)29)12-13-22(21)26(23)15-14-25(5-2)6-3/h8-13,17H,4-7,14-16H2,1-3H3; Key:CCXASIRNRBHKGD-UHFFFAOYSA-N;

Propylnitazene (PPZ) is a benzimidazole derivative which has opioid effects and has been sold as a designer drug. It is less potent than many of the "nitazene" group of opioids which have been sold on the illicit market, but is nevertheless a potent opioid drug with around fifty times the potency of morphine.^[1]^[2]^[3]^[4]

References

^ Hunger A, Kebrle J, Rossi A, Hoffmann K (1960). "Benzimidazole-Derivate und verwandte Heterocyclen III. Synthese von 1-Aminoalkyl-2-benzyl-nitro-benzimidazolen". Helvetica Chimica Acta. 43 (4): 1032–1046. doi:10.1002/hlca.19600430412.
^ Kozell LB, Eshleman AJ, Wolfrum KM, Swanson TL, Bloom SH, Benware S, et al. (April 2024). "Pharmacologic Characterization of Substituted Nitazenes at μ, κ, and Δ Opioid Receptors Suggests High Potential for Toxicity". The Journal of Pharmacology and Experimental Therapeutics. 389 (2): 219–228. doi:10.1124/jpet.123.002052. PMC 11026150. PMID 38453524.
^ Phelps C, Hardwick EK, Couch AN, Davidson JT (May 2025). "Development and validation of a combined selected ion monitoring-scan GC-EI-MS method for nitazene analogs". Journal of Forensic Sciences 1556-4029.70084. doi:10.1111/1556-4029.70084. PMID 40390160.
^ Stove CP, Vandeputte MM, Glatfelter GC, Walther D, Layle NK, Germaine DM, et al. (March 2025). "Nitazenes of the Past, Present, and Future: Insights from In Vitro µ-opioid Receptor Assays and In Vivo Behavioral Studies in Mice". The Journal of Pharmacology and Experimental Therapeutics. 392 (3) 162711. doi:10.1016/j.jpet.2024.101052.

[1] Hunger A, Kebrle J, Rossi A, Hoffmann K (1960). "Benzimidazole-Derivate und verwandte Heterocyclen III. Synthese von 1-Aminoalkyl-2-benzyl-nitro-benzimidazolen". Helvetica Chimica Acta. 43 (4): 1032–1046. doi:10.1002/hlca.19600430412.

[2] Kozell LB, Eshleman AJ, Wolfrum KM, Swanson TL, Bloom SH, Benware S, et al. (April 2024). "Pharmacologic Characterization of Substituted Nitazenes at μ, κ, and Δ Opioid Receptors Suggests High Potential for Toxicity". The Journal of Pharmacology and Experimental Therapeutics. 389 (2): 219–228. doi:10.1124/jpet.123.002052. PMC 11026150. PMID 38453524.

[3] Phelps C, Hardwick EK, Couch AN, Davidson JT (May 2025). "Development and validation of a combined selected ion monitoring-scan GC-EI-MS method for nitazene analogs". Journal of Forensic Sciences 1556-4029.70084. doi:10.1111/1556-4029.70084. PMID 40390160.

[4] Stove CP, Vandeputte MM, Glatfelter GC, Walther D, Layle NK, Germaine DM, et al. (March 2025). "Nitazenes of the Past, Present, and Future: Insights from In Vitro µ-opioid Receptor Assays and In Vivo Behavioral Studies in Mice". The Journal of Pharmacology and Experimental Therapeutics. 392 (3) 162711. doi:10.1016/j.jpet.2024.101052.

[1]

[2]

[3]

[4]

See also

References